Biogen (NASDAQ: BIIB) reported Q3 EPS of $4.81, $0.93 better than the analyst estimate of $3.88. Revenue for the quarter came in at $2.53 billion versus the consensus estimate of $2.34 billion.

GUIDANCE:

Biogen sees FY2025 EPS of $14.50-$15.00, versus the consensus of $15.76.

Increased expected full year 2025 total revenue to be approximately flat to increasing 1%, at constant currency, versus full year 2024, up from approximately flat previously

For earnings history and earnings-related data on Biogen (BIIB) click here.